Digest covering 1 recent regulatory items.
White House drug czar says cannabis is "still illegal" after rescheduling (Newsletter: May 11, 2026)
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchAgingMental Health Why This Matters Clinicians need to understand that despite the DEA's rescheduling decision,...
US Federal Policy on Medical Cannabis Rescheduling: A Step Forward with Remaining …
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchSafety Why This Matters Federal rescheduling of cannabis could legitimize prescribing practices that over 6...
DEA Reiterates Stance That Lab-Derived Cannabinoids Are Not Compliant With the Farm Bill
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchHempIndustry Why This Matters Clinicians need to understand that synthetic cannabinoids derived from hemp remain...
Selling Pot Is a Tough Business, but One California Company Is Beating the Odds – WSJ
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryTHC Clinical Summary The impending reclassification of certain cannabis products to Schedule III controlled substances...
DOJ Reschedules Medical Marijuana: Implications For Insurance Coverage, Capacity, And …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Why This Matters The DEA's rescheduling of cannabis from Schedule I to Schedule III...
Medical Marijuana Reclassification: New Research Opportunities – Observer Voice
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMedical Cannabis Why This Matters Reclassification of cannabis as a lower-controlled substance enables clinical researchers...
Should marijuana access be expanded? On April 23, 2026, the Trump administration … – Facebook
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMedical MarijuanaMental Health Clinical Summary The Trump administration’s April 2026 policy initiative, building on a...
The Biggest Things About Schedule III You Haven’t Thought Of | Cannabis Business Times
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Clinical Summary # Clinical Summary The potential rescheduling of cannabis from Schedule I to...
Federal marijuana reclassification could reshape medical research and cannabis industry
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustryAging Clinical Summary The potential federal reclassification of marijuana from Schedule I to a lower...